GlobeNewswire BiotechnologyDoubao · 实盘不做把握 8/10不做原因:无增量信息🔁 +1 同一事件
北京时间·🕒 发布 21:00:00·⟳ 抓取 21:01:35·⚡ 决策 10-14 21:03:48 +2m13s·13.2 天前
Editas Medicine预告ESGCT年会两篇LNP递送壁报及11月投资者会议，无新临床或财务数据
这是典型的会议日程预告通稿：壁报在约两周后(10月28日)才展示，摘要数据尚未公开，通稿本身不含任何临床结果、监管节点、交易或财务增量；11月的炉边谈话同样无既定新信息。公告时点对EDIT没有可交易的预期差。
📄 原文GlobeNewswire Biotechnology↗ 原文
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing com…
不做 Editas Medicine, Inc.（EDIT.US）
纯学术壁报与投资者会议日程预告，数据要到10月28日才公布，公告时点无临床/监管/财务增量、无预期差，不构成可交易催化；待壁报实际数据发布再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Editas预告ESGCT两篇临床前LNP递送壁报及11月Guggenheim会议，但无数据、无读数、无财务增量，属日程性公关稿；真正的潜在催化是10月28日壁报本身，当前不构成交易机会。
🔎 新鲜度:最早出现 2026-10-14 · 扩散 low · price-in 风险 low ↗
主要风险
- 若10月28日壁报显示体内LNP CAR-T的B细胞清除效力或安全性显著超预期，可能成为当时的独立正向催化，届时需重新研判而非依据本预告提前布局。
先例如何影响了这次决策
对本次决策的影响:未改变结论——公告本身AVOID；待10月28日真实数据发布时再按临床/临床前数据事件另做先例研究。
方向:不适用：无增量事实的学术会议日程预告不具备进入先例统计的事件实质，未据此检索/喂入先例。
涨幅量级:无幅度可校准；数据尚未发布。
形态:无
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`edit editas poster presentations esgct 33rd annual congress hamburg | editas guggenheim healthcare innovation conference november 2026 | editas medicine esgct 2026 poster lnp in vi`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen
原文全文
展开原文 · 2,525 字
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33
rd
Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.
European Society of Gene and Cell Therapy (ESGCT) Congress
Title:
Novel targeted LNP delivery achieved
in vivo
CAR-T cell generation resulting in therapeutically relevant B-cell depletion
Session Date and Time:
Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET
Session Title:
Poster Session 1
Presenter:
Harry An, Director, Process Development, Editas Medicine
Final Abstract Number:
P0361
Title:
Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeutics
Session Date and Time:
Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET
Session Title:
Poster Session 1
Presenter:
Harry An, Director, Process Development, Editas Medicine
Final Abstract Number:
P0781
Abstracts can be accessed on the conference website as they become available, and presentations will also be posted to the “
Posters & Presentations
” section of the Company’s website during the conferences.
In addition, management will participate in the following upcoming investor conference in November:
Guggenheim 3
rd
Annual Healthcare Innovation Conference
Format: Fireside Chat
Date and Time: November 10, 2026, 2:30 p.m. ET
Location: Boston, Massachusetts
To access the live webcast of Editas Medicine’s Fireside Chat, please visit the “Investors” section of the Company’s website at
www.editasmedicine.com
. An archived replay will be available for approximately 30 days following the event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative
in vivo
medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision
in vivo
gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit
www.editasmedicine.com
.
Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com
rd
Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.
European Society of Gene and Cell Therapy (ESGCT) Congress
Title:
Novel targeted LNP delivery achieved
in vivo
CAR-T cell generation resulting in therapeutically relevant B-cell depletion
Session Date and Time:
Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET
Session Title:
Poster Session 1
Presenter:
Harry An, Director, Process Development, Editas Medicine
Final Abstract Number:
P0361
Title:
Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeutics
Session Date and Time:
Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET
Session Title:
Poster Session 1
Presenter:
Harry An, Director, Process Development, Editas Medicine
Final Abstract Number:
P0781
Abstracts can be accessed on the conference website as they become available, and presentations will also be posted to the “
Posters & Presentations
” section of the Company’s website during the conferences.
In addition, management will participate in the following upcoming investor conference in November:
Guggenheim 3
rd
Annual Healthcare Innovation Conference
Format: Fireside Chat
Date and Time: November 10, 2026, 2:30 p.m. ET
Location: Boston, Massachusetts
To access the live webcast of Editas Medicine’s Fireside Chat, please visit the “Investors” section of the Company’s website at
www.editasmedicine.com
. An archived replay will be available for approximately 30 days following the event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative
in vivo
medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision
in vivo
gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit
www.editasmedicine.com
.
Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ee6ec9634a· 2026-10-14 21:03 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前